MOLECULAR AND CELLULAR FACTORS OF LOCAL IMMUNITY IN ASCITIC FLUID OF OVARIAN CANCER PATIENTS

DOI: https://doi.org/None

E.Yu. Zlatnik, G.A. Nerodo, I.A. Novikova, A.V. Bakhtin, G.I. Zakora, O.N. Selyutina, A.Yu. Ardzha Rostov Research Institute of Oncology, 14 Line, 63, Rostov-on-Don, 344037, Russian Federation

Introduction. Immunologic microenvironment of malignant tumors is likely to be significant in «tumor-host» interaction. The aim of the study. Сomparative analysis of systemic and local factors of cellular and humoral immunity in patients with ascitic forms of ovarian cancer. Methods. Subsets of lymphocytes in samples of blood and ascitic fluid of patients with ovarian cancer were counted by flow cytometry on BD FACSCantoII (BD, USA); levels of cytokines and immunoglobulins were tested by ELISA-method. Results. In ascitic fluid levels of pro- and antiinflammatory cytokines as well as of monocytes and lymphocytes, predominantly of memory T-cells, were higher whereas the number of naive T-cells and immunoglobulins was lower than in blood of patients. Conclusion. Thus factors of local immunity may take part in formation of the growth-stimulating and immunosuppressive microenvironment of ovarian cancer.
Keywords: 
ovarian cancer, local immunity, flow cytometry, ELISA, memory T-cells, cytokines

Список литературы: 
  1. Haitov R.M. Fiziologiya immunnoy sistemy.sistemy. M.: VINITI RAN, 2001; 222.[Khaitov R.M. Physiology of the immune system. M.: VINITI RAN, 2001; 222 (in Russian)]
  2. Yarilin A.A. Osnovy immunologii. M.: Medicina, 1999; 456.[Yarilin A.A. Basics of immunology. M.: Meditsina, 1999; 456 (in Russian)]
  3. Balkwill F. Cancer and the chemokine network. Nat. Res. Cancer. 2004; 4 (7): 540–50.
  4. Berezhnaya N.M., Chehun V.F. Immunologiya zlokachestvennogo rosta. Kiev: Naukova Dumka, 2005; 790.[Berezhnaya N.M., Chekhun V.F. Immunology of malignant growth. Kiev: Naukova Dumka, 2005; 790 (in Russian)]
  5. Fidler I.J. The organ microenvironvent and cancer metastasis. Differentiation. 2002; 70 (9–10): 498–505
  6. Lewis C.E., Pollard W.J. Distinct role of macrophages in different tumor microenvirontments. Cancer res. 2006; 66 (2): 605–12.
  7. Zlatnik E.Yu., Men`shenina A.P., Ushakova N.D., Zakora G.I., Mkrtchan E`.T. Lokal`nye urovni faktorov gumoral`nogo immuniteta v asciticheskoy zhidkosti bol`nyh rakom yaichnika. Ross. allergol. zhurn. 2012; 5 (1): 95–6.[Zlatnik E.Yu., Menshenina A.P., Ushakova N.D., Zakora G.I., Mkrtchyan E.T. Local levels of humoral immunity factors in ascitic fluid of ovarian cancer patients. Russian Allergology J. 2012; 5 (1): 95–6 (in Russian)]
  8. Zlatnik E., Nerodo G., Mordan A., Mkrtchyan E. Factors of local immunity in patients with ovarian cancer. Eur. J. of Cancer. 2013; 49 (suppl. 2): 733.
  9. Antoneeva I.I. Dinamika urovnya citokinov v krovi bol`nyh rakom yaichnikov pri progressirovanii opuholi. Vestnik RUDN. Seriya Medicina. 2007; 6: 479–82.[Antoneeva I.I. Dynamics of the level of cytokines in blood of ovarian cancer patients in the tumor progression. Vestnik RUDN. Ser. Meditsina. 2007; 6: 479–82 (in Russian)]
  10. Sel`chuk V.Yu., Bychkov M.B., Kiselevskiy M.V. Opuholevye serozity: plevrity, ascity, perikardity. M.: Prakticheskaya medicina, 2011; 278.[Selchuk V.Yu., Bychkov M.B., Kiselevskiy M.V. Tumoral serositis: pleurisy, ascites, pericarditis. M.: Prakticheskaya meditsina, 2011; 278 (in Russian)]
  11. Golotina L.Yu., Zlatnik E.Yu. Opyt primeneniya LAK-terapii s ronkoleykinom v kompleksnom lechenii raka yaichnika. Vopr. onkol. 2013; 59 (3): 52–3.[Golotina L.Yu., Zlatnik E.Yu. Experience of application of LAK-therapy with roncoleukin in complex treatment for ovarian cancer. Voprosy Onkologii. 2013; 59 (3): 52–3 (in Russian)]
  12. Antoneeva I.I. Differencirovochnye i aktivacionnye markery limfocitov perifericheskoy krovi bol`nyh rakom yaichnikov v dinamike opuholevoy progressii. Med. immunologiya. 2007; 9 (6): 643–9.[Antoneeva I.I. Differentiation and activation markers of peripheral blood lymphocytes in ovarian cancer patients in dynamics of the tumor progression. Medical Immunology (Russia). 2007; 9 (6): 643–9 (in Russian)]
  13. Kurganova E.V., Tihonova M.A., Lebedeva V.A., Laskavaya E.G., Kovalenko V.F., Ostanin A.A., Chernyh E.R. Harakteristika regulyatornyh T-kletok u bol`nyh rakom yaichnika. Sibirskiy onkol. zhurn. 2008; 30 (6): 40–5.[Kurganova E.V., Tikhonova M.A., Lebedeva V.A., Laskavaya E.G., Kovalenko V.F., Ostanin A.A., Chernykh E.R. Characteristics of regulatory T-cells in ovarian cancer patients. Sibirskiy onkologicheskiy zhurnal. 2008; 30 (6): 40–5 (in Russian)]
  14. Laskavaya E.G., Lebedeva V.A., Narov Yu.I., Tihonova M.A., Kurganova E.V., Ostanin A.A., Chernyh E.R. Regulyatornye CD4+ i CD8+ kletki u bol`nyh s dobrokachestvennymi i zlokachestvennymi obrazovaniyami yaichnikov. Sibirskiy onkol. zhurn. 2010; 1: 67–8.[Laskavaya E.G., Lebedeva V.A., Narov Yu.I., Tikhonova M.A., Kurganova E.V., Ostanin A.A., Chernykh E.R. Regulatory CD4+ and CD8+ cells in patients with benign and malignant ovarian neoplasms. Sibirskiy onkologicheskiy zhurnal. 2010; 1: 67–8 (in Russian)]
  15. Seledcov V.I., Litvinova L.S., Goncharov A.G., Shulepcova V.V., Seledcov D.V., Gucol A.A., Seledcova I.A. Kletochnye mehanizmy generacii immunologicheskoy pamyati. Citokiny i vospalenie. 2010; 9 (4): 9–15.[Seledtsov V.I., Litvinova L.S., Goncharov A.G., Shuleptsova V.V., Seledtsov D.V., Gutsol A.A., Seledtsova I.A. Cellular mechanisms of generation of immunological memory. Cytokines and Inflammation. 2010; 9 (4): 9–15 (in Russian)]
  16. Chu T., Tyznik A.J., Roepke S., Berkley A.M., Woodward-Davis A., Pattacini L., Bevan M.J., Zehn D. and Prlic M. Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Reports. 2013; 3 (3): 701–8.
  17. Klebanoff C.A. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102 (27): 9571–6.
  18. Nakamura Y., Watchmaker P., Urban J., Sheridan B., Giermasz A., Nishimura F., Sasaki K., Cumberland R. Helper function of memory CD8+ T cells; heterologous CD8+ T cells support induction of therapeutic cancer immunity. Cancer res. 2007; 67 (1): 10012–8.
  19. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P.H., Trajanosky Z., Fridman W.H., Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005; 353 (25): 2654–66.
  20. Motz G.T., Santoro S.P., Wang L.P., Wang L.P., Garrabrant T., Lastra R.R., Hagemann I.S., Lal P., Feldman M.D., Benencia F., Coukos G. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 2014; 20 (6): 607–15.